Abstract |
To develop CpG oligodeoxynucleotides (CpG ODNs) based therapy for prevention and treatment of severe acute respiratory syndrome (SARS), we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3', and tested for its anti-SARS-CoV activity. We found that the supernatants of human PBMCs stimulated by BW001 significantly protected Vero cells from SARS-CoV infection. BW001 could stimulate human PBMCs and pDCs to secrete high level of IFN-alpha and promote human PBMCs and B cells to proliferate. Furthermore, we demonstrated that BW001 could activate CD19+ B cells and CD56+ NK cells in human PBMCs. In addition, BW001 could enhance NK cytotoxicity and IFN-gamma secretion in human PBMCs. Together, BW001 represents a novel type of CpG ODN and may have potential for the development of treatment and prevention for SARS as well as other viral associated diseases.
|
Authors | Musheng Bao, Yi Zhang, Min Wan, Li Dai, Xiaoping Hu, Xiuli Wu, Li Wang, Ping Deng, Junzhi Wang, Jianzhu Chen, Yongjun Liu, Yongli Yu, Liying Wang |
Journal | Clinical immunology (Orlando, Fla.)
(Clin Immunol)
2006 Feb-Mar
Vol. 118
Issue 2-3
Pg. 180-7
ISSN: 1521-6616 [Print] United States |
PMID | 16298165
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adjuvants, Immunologic
- Antiviral Agents
- CPG-oligonucleotide
- Oligodeoxyribonucleotides
|
Topics |
- Adjuvants, Immunologic
(pharmacology)
- Animals
- Antiviral Agents
(pharmacology)
- B-Lymphocytes
(immunology, virology)
- Cell Line
- Chlorocebus aethiops
- CpG Islands
(immunology)
- Cytotoxicity Tests, Immunologic
- Humans
- Killer Cells, Natural
(immunology, virology)
- Leukocytes, Mononuclear
(immunology, virology)
- Lymphocyte Activation
(immunology)
- Oligodeoxyribonucleotides
(immunology)
- Severe acute respiratory syndrome-related coronavirus
(immunology)
- Severe Acute Respiratory Syndrome
(immunology, prevention & control)
- Vero Cells
|